Lactose (India) Ltd.
Snapshot View

77.50 +3.65 ▲4.9%

20 May 2022, 01:25:00 PM
Volume: 4,365

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.lactoseindia.com
Market Cap 97.56 Cr.
Enterprise Value(EV) 131.85 Cr. 2022-03
Financial Indicators
Earnings per share (EPS) 1.95 Trailing Twelve Months Ending 2022-03
Price-Earning Ratio (PE) 39.82 Trailing Twelve Months Ending 2022-03
Industry PE 28.47 Trailing Twelve Months Ending 2022-03
Book Value / Share 31.21 Trailing Twelve Months Ending 2022-03
Price to Book Value 2.48 Calculated using Price: 77.50
Dividend Yield 0.00 Period Ending 2021-03
No. of Shares Subscribed 1.26 Cr. 12,589,000 Shares
FaceValue 10
Company Profile

Lactose (India), a Toshniwal Group company, was incorporated in 1991, under the Companies Act, 1956. Its  plant in Vadodara, Gujarat was commissioned by Alfa Laval, Pune (which is a subsidary of Alfa Laval of Sweden) and was also given a ‘thumbs up’ by reputed dairy experts from the Netherlands in October 1991. Subsequently Alfa Laval, reputed dairy experts from Sweden and a joint commission from the Netherlands studied the plant and its working and confidently acknowledged the plant for its quality standards as well.

For ten years now, Lactose (India) Limited has stood for perfection, quality, constant innovation and complete dedication to their clients. With up to date technology, the company is one of India's leading producers of Edible and Pharmaceutical grade Lactose. Apart from this, the company also manufactures Dairy Whitener, Dairy Calcium, Whey Powder, Casein, Caseinate, Butter and Ghee.

The company still boasts of being the first company to manufacture Lactose in the Asian subcontinent. The company has since grown to be a leading player in the Lactose market and continues to supply consistent quality Lactose to several global giants in the pharmaceutical world. It commands a 40% overall market share and this makes the company the leading Lactose supplier in the country.

With its unparalled infrastructure of requisite equipment and dedicated work force, Lactose (India) has a state of the art manufacturing facility for contract manufacturing of pharmaceutical products.The latest in its diverse interests is the manufacturing of pharmaceutical formulations for Aventis Pharma (earlier-Hoechst Marion Roussel), for the purpose of domestic use and export to Russia.

The state of art manufacturing facilities for the manufacture of pharmacuetical formulations is in compliance with all international standards.The plant is approved under WHO-cGMP guidelines and also holds TUV certificate as an ISO 9001 : 2000 company.The manufacturing facilities include wet granulation,Fluid bed drying, compaction, blending and coating facilities with the latest technology equipments.The manufacturing facilities is well supported by its total in-house Quality Control set-up with latest Testing equipments and an upto date Microbiology Testing Laboratory. The facility is supported by an equally competent and FDA approved Manufacturing professionals.

Besides providing lactose for pharmaceutical giants, food,confectionary and dairy companies in India, the company's product also leaves Indian shores for the African continent, South East Asia, and some of its other neighbouring countries.

After achieving its ambitious goal of being the most successful and leading Lactose manufacturer and supplier in the country, the company is now venturing aggressively into exports of pharmaceuticals and related products.

Product range of the company includes:

  • Edible and Pharmaceutical grade Lactose
  • Dairy Whitener
  • Dairy Calcium
  • Whey Powder
  • Casein
  • Caseinate
  • Butter and Ghee.

Awards & Achievements:

  • TUV Certificate
  • An ISO 9001:2000 Certified company

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+4.94%
1 Week
+17.25%
1 Month
+11.03%
3 Month
+43.65%
6 Month
+100.52%
1 Year
+168.63%
2 Year
+323.50%
5 Year
-41.24%
10 Year
+715.79%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 7.14 0.18 3.25 15.69 11.95 -4.59 2.20 0.21 -7.21
Return on Capital Employed (%) 9.25 3.69 7.55 14.75 14.78 4.08 9.13 7.84 2.81
Return on Assets (%) 2.35 0.05 0.71 3.44 3.30 -1.59 0.88 0.09 -2.88

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03* Rs. Cr.
Shh. Funds 15 15 16 20 27 32 34 34 35 39
Non Curr. Liab. 15 30 44 37 31 38 35 38 42 36
Curr. Liab. 17 16 20 26 27 13 12 11 12 15
Minority Int.
Equity & Liab. 47 60 80 83 85 83 82 84 88 90
Non Curr. Assets 27 47 67 66 68 66 64 64 69 67
Curr. Assets 20 13 13 17 17 17 18 20 20 23
Misc. Exp. not W/O
Total Assets 47 60 80 83 85 83 82 84 88 90

Profit Loss View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. TTM
Net Sales 47 22 24 34 36 31 41 40 35 46
Other Income 1 1 0 1 1 1 0 0 0 1
Total Income 47 23 24 36 37 32 41 40 35 47
Total Expenditure -44 -21 -19 -24 -24 -25 -31 -31 -29 -34
PBIDT 4 2 5 12 12 6 10 10 7 13
Interest -1 -1 -3 -4 -4 -5 -5 -6 -5 -5
Depreciation -2 -2 -2 -3 -3 -4 -4 -4 -4 -5
Taxation 0 0 0 -1 -2 1 0 0 1 -1
Exceptional Items 2
PAT 1 0 1 3 3 -1 1 0 -2 2
Adjusted EPS 1 0 1 3 3 -1 1 0 -2 2

Cash Flow View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. -3 14 7 13 1 8 0 5 7 2
Cash Fr. Inv. -3 -14 -21 -23 3 -5 -2 -2 -3 -6
Cash Fr. Finan. 6 1 13 10 -5 -3 4 -5 -4 5
Net Change 0 1 -1 -1 0 0 3 -2 1 1
Cash & Cash Eqvt 0 1 1 0 0 0 3 1 2 2

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 42.90 42.90 42.90 42.90 49.13 49.13 49.13 52.50 53.79
Public 57.10 57.10 57.10 57.10 50.87 50.87 50.87 47.50 46.21
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 3.94 3.94 60.61 60.61 47.15 47.15 47.15 41.21 39.13

Announcements View Details

Thu, 19 May 2022
Announcement under Regulation 30 (LODR)-Newspaper Publication
In terms of Regulation 30 and Regulation 47(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (LODR) please find attached newspaper cuttings of the advertisement in relation to the financial results for the fourth quarter and Financial Year ended on 31st March 2022 as specified in Regulation 33 of LODR published in Business Standard (English) and Vadodara Samachar (Gujarati) on 19th May 2022.
Tue, 17 May 2022
Board Meeting Outcome for Board Meeting Held On 17Th May 2022
In compliance with Regulation 30 and 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 this is to inform that the Board of Directors of the Company at their meeting held on 17th May 2022 has inter alia considered and approved the followings items of agenda:
1. Audited Financial Results along with Auditors Report for the Fourth quarter and Financial year ended 31st March 2022;

2. Audited Financial Statements of the company for the Financial year ended 31st March 2022;


3. Re-appointment of Internal Auditor for FY 2022-23;

4. Noting of resignation of M/s. Jajodia & Associates Secretarial Auditor of the company;

5. Appointment of Ms. Bhumika Sidhpura as Secretarial Auditor of the company for the FY 2021-2022 & 2022-2023;
Tue, 17 May 2022
Intimation Regarding Resignation Of Secretarial Auditor Pursuant To Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 ("Listing Regulations").
Pursuant to Regulation 30 read with Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that M/s. Jajodia & Associates Practicing Company Secretaries has resigned as the Secretarial Auditor of the Company due to pre occupation for Financial year 2021-2022 vide resignation letter 16th May 2022.

Technical Scans View Details

Thu, 19 May 2022
High Delivery Percentage High Delivery Percentage
Higher Delivery Quantity Higher Delivery Quantity
Higher Delivery Quantity and Percentage Higher Delivery Quantity and Percentage
Close Crossing Last Month Close From Below Close Crossing Last Month Close From Below
Opening at High Opening at High

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 212,197.18 909.00 +2.8%
Divi's Laboratories Ltd. 111,510.08 4,284.00 +2.0%
Cipla Ltd. 75,683.19 973.10 +3.7%
Dr. Reddy's Laboratories Ltd. 65,571.78 4,244.00 +8.0%
Apollo Hospitals Enterprise Ltd. 52,245.59 3,664.65 +0.9%
Gland Pharma Ltd. 51,277.11 3,063.35 -1.2%
Piramal Enterprises Ltd. 45,274.50 1,919.95 +1.4%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 32.93 909.00 +2.8%
Divi's Laboratories Ltd. Consolidated 2021-12 43.43 4,284.00 +2.0%
Cipla Ltd. Consolidated 2022-03 30.07 973.10 +3.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 30.04 4,244.00 +8.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 46.10 3,664.65 +0.9%
Gland Pharma Ltd. Consolidated 2021-12 43.23 3,063.35 -1.2%
Piramal Enterprises Ltd. Consolidated 2021-12 36.44 1,919.95 +1.4%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.11 909.00 +2.8%
Divi's Laboratories Ltd. Consolidated 2021-12 10.30 4,284.00 +2.0%
Cipla Ltd. Consolidated 2022-03 3.63 973.10 +3.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.41 4,244.00 +8.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.44 3,664.65 +0.9%
Gland Pharma Ltd. Consolidated 2021-12 7.47 3,063.35 -1.2%
Piramal Enterprises Ltd. Consolidated 2021-12 1.28 1,919.95 +1.4%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 909.00 +2.8%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,284.00 +2.0%
Cipla Ltd. Consolidated 2021-03 0.10 973.10 +3.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,244.00 +8.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,664.65 +0.9%
Gland Pharma Ltd. Consolidated 2021-03 0.00 3,063.35 -1.2%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 1,919.95 +1.4%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 909.00 +2.8%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,284.00 +2.0%
Cipla Ltd. Consolidated 2021-03 14.13 973.10 +3.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,244.00 +8.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,664.65 +0.9%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,063.35 -1.2%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,919.95 +1.4%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 909.00 +2.8%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,284.00 +2.0%
Cipla Ltd. Consolidated 2021-03 14.13 973.10 +3.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,244.00 +8.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,664.65 +0.9%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,063.35 -1.2%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,919.95 +1.4%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 909.00 +2.8%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,284.00 +2.0%
Cipla Ltd. Consolidated 2021-03 19,159.59 973.10 +3.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,244.00 +8.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,664.65 +0.9%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 3,063.35 -1.2%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 1,919.95 +1.4%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 909.00 +2.8%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,284.00 +2.0%
Cipla Ltd. Consolidated 2021-03 2,401.30 973.10 +3.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,244.00 +8.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,664.65 +0.9%
Gland Pharma Ltd. Consolidated 2021-03 996.96 3,063.35 -1.2%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 1,919.95 +1.4%